International Meeting on Clinical and Laboratory Genomic Standards - PowerPoint PPT Presentation

1 / 12
About This Presentation
Title:

International Meeting on Clinical and Laboratory Genomic Standards

Description:

Kathy Zoon. Working together is success. Pharmacogenomic and pharmacogenetic assays ... Technical working groups: Dr. Zoon, Dr. Barton. Policy working groups: ... – PowerPoint PPT presentation

Number of Views:48
Avg rating:3.0/5.0
Slides: 13
Provided by: affy
Category:

less

Transcript and Presenter's Notes

Title: International Meeting on Clinical and Laboratory Genomic Standards


1
International Meeting on Clinical and Laboratory
Genomic Standards
  • 3-5, May 2005
  • Paris
  • Janet A. Warrington, Ph.D.
  • Vice President
  • Affymetrix Inc.

2
Planning Committee
  • Joe Boone
  • Jean Jacques Cassiman
  • Philippe Corbisier
  • Edison Liu
  • Thane Kreiner
  • Vincent L. Vilker
  • Janet A. Warrington
  • Robert Wells
  • Kathy Zoon

3
Working together is success
  • Pharmacogenomic and pharmacogenetic assays
  • raise complex issues difficult for pharma
  • and biotech to resolve (alone)
  • Standardization requires community efforts

Ito R.I., and Demers L. M., 2004 Clin Chem.
501526-27
4
Goals and outcomes
  • Meeting goals
  • Increase stakeholder interaction
  • Accelerate development of guidelines, shared
    materials
  • Desired outcomes
  • Identify areas where harmonization is possible
    and practical and areas where it is not
  • Identify initiatives that would benefit from the
    international community
  • working together
  • Identify areas that need to be addressed, where
    new working
  • groups are needed
  • Prioritize issues
  • Identify next steps for moving forward
  • Meeting summary Dr. Susan Aldridge

5
Meeting Overview
  • Case study examples in rapidly developing areas
  • Address current status
  • Standard controls and reference materials
  • Reporting standards
  • Probabilistic outcome decision making
  • Ethical and legal issues associated with
    probabilistic outcome decision making
  • Panels to discuss key activities, challenges,
    priorities
  • Working groups to identify priorities, next steps

6
Agenda
  • Wednesday, May 4, 2005
  • Case Studies
  • 900 AM High Complexity Gene Expression Based
    Tests, Dr. Haferlach
  • 1000 AM Break
  • 1015 AM Implementation of cyp450 Testing in a
    Hospital-Based
  • Clinical Laboratory Setting, Dr. Farkas
  • 1045 AM Molecular Karyotyping An Example of
    a High Complexity DNA
    Based Test, Dr.Vermeesch
  • 1115am The Cystic Fibrosis Model for Genetic
    Test Result Reporting
  • Applicability to Clinical Direct Mutation
    and Sequence
  • Analysis, Dr. Lubin
  • 1215pm Lunch at the Hotel DAubusson

7
Agenda
  • Wednesday, May 4, 2005
  • 145pm Roundtable Discussion Technical Panel
  • Dr. OConnell, Dr. Foy, Dr.Elles, Dr. Ueda
  • 330pm Break
  • 345pm Roundtable Discussion Policy Panel Dr.
    Ronchi, Dr. Sanne, Dr. Chan, Mr. Doheny
  • 530pm Free Time
  • 640 pm Meet in lobby and walk to Lapérouse
  • 700pm Dinner at Lapérouse

8
Agenda
  • Thursday, May 5, 2005
  • 730am Breakfast in the Hotel DAubusson
  • 845am Review agenda for the day
  • 900am Working Groups
  • Technical working groups Dr. Zoon, Dr. Barton
  • Policy working groups Dr. Liu, Dr. Cassiman
  • 1030am Break
  • 1045am Continue discussion Panel chairs present
    summaries
  • of next steps
  • 1200pm Working lunch
  • 100pm Adjourn

9
Technical Working Groups
Group 1 Leader Dr.Zoon Dahlman-Wright Forrest F
urukawa Haferlach Landegren OConnell Parkes Reid
l
Group 2 Leader Dr.Barton Canneiux Corbissier Ell
es Foy Lubin Salit Ueda Tirrell
10
Policy Working Groups
Group 3 Leader Dr. Cassiman Cao Chan Doheny Ibar
etta Kreiner Madej Rousseau Sun
Group 4 Leader Dr.Liu Carlstedt-Duke Farkas Mans
field Passioukov Ronchi Sanne Wells
11
Definitions
  • Pharmacogenetic Test (PGe)
  • An assay intended to study interindividual
    variations in DNA sequence related to drug
    absorption and disposition (pharmacokinetics) or
    drug action (pahrmacodynamics), including
    polymorphic variation in the genes that encode
    the functions of transporters, metabolizing
    enzymes, receptors and other proteins.
  • Pharmacogenomic Test (PGo)
  • An assay intended to study interindividual
    variations in whole-genome or candidate genes,
    SNP maps, haplotype markers, or alterations in
    gene expression or inactivation that may be
    correlated with pharmacological functionand
    therapeutic response. In some cases, the pattern
    or profile of change is the relevant biomarker,
    rather than the changes in individual markers.

Attachment to Guidance on Pharmacogenomic Data
Submissions U.S. Dept. HHS, FDA, March 2005
12
Rules of Engagement
  • Opinions expressed represent individual expert
    opinion and are not meant to represent the
    official position of any organization unless
    explicitly stated.
  • To indicate that you wish to participate in the
    discussion please set your tent card on end.
Write a Comment
User Comments (0)
About PowerShow.com